CFF Awards $2.4M to Advance CB-280 in Preventing Lung Infections
The Cystic Fibrosis Foundation (CFF) has awarded up to $2.4 million to Calithera Biosciences to advance in testing CB-280, its investigative oral therapy that aiming to lower the risk of lung infections in people with cystic fibrosis (CF). An enrolling clinical trial is underway in…